Angiochem peptide drug conjugate enters phase IIb in HER2+ breast cancer
Despite rumors to the contrary, news coming from the American Society of Clinical Oncology (ASCO) meeting in Chicago was not entirely focused on immunotherapy. Privately held Angiochem Inc. was among the companies reporting positive findings from candidates with other mechanisms of action. Angiochem's lead molecule, ANG1005, is a paclitaxel-peptide drug conjugate and the first drug of its kind to leverage the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. At ASCO, the company reported findings from phase I and initial phase II studies in HER2+ and HER2-negative breast cancer.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter